RNA antibiotics
A Digital Approach to Novel RNA Antibiotics to fight diseases

Conventional antibiotics generally work against a broad spectrum of bacterial pathogens. This promotes the development of antibiotic resistance and damages our protective microbiota, which can have unwanted effects on our health. New antibiotics are therefore needed that can directly target individual pathogens, leaving beneficial bacteria unharmed. In a multidisciplinary approach, our team is researching antibiotics based on RNA-like molecules, so-called peptide nucleic acids (PNA), which can be used to specifically attack individual bacterial strains. These RNA antibiotics can be modified through simple chemical means to achieve effectiveness against emerging pathogens. In order to automate this process, we are creating a digital platform using high-throughput processes and machine learning, that will enable researchers to specifically design drug molecules against a variety of dangerous pathogens.

Strategy and conditions

Peptide nucleic acids are RNA-like molecules that bind to messenger RNA through complementary base pairing and can inhibit the production of proteins. This approach has already been confirmed to be effective in preclinical studies, but there are many open questions, for instance about the rules for programming such RNA antibiotics, mechanisms of resistance development, and possible toxicity to host cells and non-targeted members of the microbiome. We are pursuing a combination of transcriptome analysis and machine learning to understand the effects of PNAs on bacterial pathogens and to identify effective PNA candidates.

Aims of the research project

The goal of our research is to establish effective PNA candidates for important clinical pathogens. Towards this purpose, we will characterize the molecular basis of PNA activity and resistance development through the systematic analysis of high-throughput data. The knowledge we gain from these studies will form the basis for future logic design of RNA antibiotics to use against multi-drug resistant pathogens and editing the microbiome.

PNA coupling
Expected benefits for society

The development of programmable antibiotics will have major implications for the treatment of infection: as only the particular strain targeted is affected, issues of resistance development in other bacteria can be avoided. Additionally, this approach will avoid harming our natural commensal bacteria. This strategy could also be used to target specific functions of bacteria, for instance so that resistant bacteria become sensitive to conventional antibiotics, or pathogens no longer express toxins. Since certain bacterial pathogens are also associated with tumorigenesis, RNA antibiotics could also be of interest for cancer treatment or prophylaxis in the future.


Prof. Dr. Jörg Vogel
Project Management

Universität Würzburg
Medizinische Fakultät
Institut für Molekulare Infektionsbiologie

Dr. Franziska Faber
Project Management

Universität Würzburg
Medizinische Fakultät
Institut für Molekulare Infektionsbiologie

Jun. Prof. Dr. Lars Barquist
Project Management

Universität Würzburg
Medizinische Fakultät
Institut für Molekulare Infektionsbiologie

Julius-Maximilians-Universität Würzburg
Medizinische Fakultät
Institut für Molekulare Infektionsbiologie

  • repeat-associated small RNA con-trols the major virulence factors of Helicobacter py-lori
    Sara K. Eisenbart, Mona Alzheimer, et.al., Cynthia M. Sharma;
    Molecular Cell 2020
  • Proton Motive Force Disruptors Block Bacterial Competence and Horizontal Gene Transfer.
    Domenech A, Brochado AR, Sender V, Hentrich K, Henriques-Normark B, Typas A and Veening JW
    Cell Host Microbe 2020
  • A three-dimensional intestinal tissue model reveals factors and small regulatory RNAs important for colonization with Campylobacter jejuni.
    Alzheimer M, Svensson SL, König F, Schweinlin M, Metzger M, Walles H, Sharma CM
    PLoS Pathogens 2020
  • Precursors for Nonlymphoid-Tissue Treg Cells Reside in Secondary Lymphoid Organs and Are Programmed by the Transcription Factor BATF.
    Delacher M, Imbusch CD, Hotz-Wagenblatt A, Mallm JP, Bauer K, Simon M, Riegel D, Rendeiro AF, Bittner S, Sanderink L, Pant A, Schmidleithner L, Braband KL, Echtenachter B, Fischer A, Giunchiglia V, Hoffmann P, Edinger M, Bock C, Rehli M, Brors B, Schmidl C, Feuerer M.
    Immunity 2020
  • Microbial networks in SPRING – Semi-parametric rank-based correlation and partial correlation estimation for quantitative microbiome data.
    Yoon G, Gaynanova I, Müller CL
    Frontiers in Genetics 2019
  • Rbpj expression in regulatory T cells is critical for restraining TH2 responses.
    Delacher M, Schmidl C, Herzig Y, Breloer M, Hartmann W, Brunk F, Kägebein D, Träger U, Hofer AC, Bittner S, Weichenhan D, Imbusch CD, Hotz-Wagenblatt A, Hielscher T, Breiling A, Federico G, Gröne, HJ, Schmid RM, Rehli M, Abramson J, Feuerer M.
    Nat Commun. 2019
  • HIF1A and NFAT5 coordinate Na+-boosted antibacterial defense via enhanced autophagy and autolysosomal targeting.
    Neubert, P., Weichselbaum, A., Reitinger, C., Schatz, V., Schröder, A., Ferdinand, J.R., Simon, M., Bär, A.L., Brochhausen, C, Gerlach, R.G., Tomiuk, S., Hammer, K., Wagner, S., van Zandbergen, G., Binger, K.J., Müller, D.N., Kitada, K., Clatworthy, M.R., Kurts, C., Titze, J., Abdullah, Z., Jantsch, J.
    Autophagy 2019
  • Limitation of TCA Cycle Intermediates Represents an Oxygen-Independent Nutritional Antibacterial Effector Mechanism of Macrophages.
    Hayek, I., Fischer, F., Schulze-Luehrmann, J., Dettmer, K., Sobotta, K., Schatz, V., Kohl, L., Boden, K., Lang, R., Oefner, P.J., Wirtz, S., Jantsch, J.*, Lührmann, A*.
    Cell Rep. 2019
  • Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps.
    Ailloud F, Didelot X, Woltemate S, Pfaffinger G, Overmann, J, Bader RC, Schulz C, Malfertheiner P, Suerbaum S
    Nat Commun. 2019
  • Deep learning: new computational modelling techniques for genomics.
    Eraslan G, Avsec Ž, Gagneur J, Theis FJ.
    Nat Rev Genet. 2019
  • Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
    Menden MP, Wang D, Mason MJ, Szalai B, Bulusu KC, Guan Y, Yu T, Kang J, Jeon M, Wolfinger R, Nguyen T, Zaslavskiy M; AstraZeneca-Sanger Drug Combination DREAM Consortium, Jang IS, Ghazoui Z, Ahsen ME, Vogel R, Neto EC, Norman T, Tang EKY, Garnett MJ, Veroli GYD, Fawell S, Stolovitzky G, Guinney J, Dry JR, Saez-Rodriguez J.
    Nat Commun. 2019
  • Fungi Stabilize Connectivity in Lung and Skin Microbial Ecosystems.
    Tipton L*, Müller CL*, Kurtz ZD, Morris A, Huang L, Kleerup E, Bonneau R, Ghedin E
    Microbiome 2018
  • Extensive impact of non-antibiotic drugs on human gut bacteria.
    Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A
    Nature 2018
  • CRISPR RNA-dependent binding and cleavage of endogenous RNAs by the Campylobacter jejuni Cas9.
    Dugar G, Leenay RT, Eisenbart SK, Bischler T, Aul BU, Beisel CL, Sharma CM
    Molecular Cell 2018
  • Species-specific activity of antibacterial drug combinations
    Brochado AR, Telzerow R, Bobonis J, Banzhaf M, Mateus A, Selkrig J, Huth E,Bassler S, Zamarreño J, Zietek M, Ng N, Foerster S, Ezraty B, Py B, Barras F, Savitski MM, Bork P, Göttig S, Typas A
    Nature 2018
  • p62/sequestosome 1 deficiency accelerates osteo- clastogenesis in vitro and leads to Paget’s disease-like bone phenotypes in mice.
    Zach F, Polzer F, Mueller A, Gessner A.
    J Biol Chem. 2018
  • Dectin-1 positive dendritic cells expand after infection with Leishmania major parasites and represent promising targets for vaccine development.
    Zimara N., Menberework C., Abraham A., van Zandbergen G., Lepenies B., Schmid M., Weiss R., Rascle A., Wege A.K, Jantsch J., Schatz V., Brown G.D and Ritter U.
    Frontiers in Immunology 2018
  • Identifying dormant growth state of mycobacteria by orthogonal analytical approaches on a single cell and ensemble basis.
    Neumann AC, Bauer D, Hölscher M, Haisch C, Wieser A.
    American Chemical Society 2018
  • A single early-in-life antibiotic course has long-lasting effects on microbial network topology and host immunity.
    Müller CL, Cadwell K, Bonneau R, Perez-Perez GI, Blaser MJ
    Nat Commun. 2017
  • Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.
    Asare Y, Ommer M, Azombo FA, Alampour-Rajabi S, Sternkopf M, Sanati M, Gijbels MJ, Schmitz C,Sinitski D, Tilstam PV, Lue H, Gessner A, Lange D, Schmid JA, Weber C, Dichgans M, Jankowski J, Pardi R, de Winther MP, Noels H, Bernhagen J.
    Proc Natl Acad Sci U S A. 2017
  • Transcriptional programs controlling the expression of the Autoimmuneregulator gene.
    Herzig Y, Nevo S, Bornstein C, BrezisMR, Ben-Hur S, Shkedy A, Eisenberg-Bord M, Levi B, Delacher M, Goldfarb Y, David E, Weinberger L, Viukov S, Ben-Dor S, Giraud M, Hanna JH, Breiling A, Lyko F, Amit I,Feuerer M, Abramson J.
    Nature Immunology 2017
  • Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues
    Delacher M, Imbusch CD, Weichenhan D, Breiling A, Hotz-Wagenblatt A, Träger U, Hofer AC, Kägebein, D, Wang Q, Frauhammer F, Mallm JP, Bauer K, Herrmann C, Lang PA, Brors B, Plass C, Feuerer M.
    Nature Immunology 2017
  • DC subset specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo
    Lehmann CHK, Baranska A, Heidkamp GF, Heger L, Neubert K, Lühr JJ, Hoffmann A, Reimer K, Brückner, C, Beck S, Seeling M, Kießling M, Soulat D, Krug A, Ravetch JV, Jeanette H. W. Leusen JHW, Nimmerjahn, F, Dudziak D.
    J. Exp. Med 2017
  • Reference Point Insensitive Molecular Data Analysis Affiliations.
    Altenbuchinger, M., Rehberg, T., Zacharias, H. U., Stämmler, F., Dettmer, K., Weber , D., Hiergeist, A., Gessner, A., Holler , E., Oefner, P. J., Spang, R.
    Bioinformatics 2017
  • Global Prevalence of Helicobacter pylori infection: systematic review and meta-analysis.
    Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingo D, Malfertheiner P, Graham DY, Wong VWS, Wu JCy, Chan FKL, Sung JJY, Kaplan GG, Ng SC
    Gastroenterol 2017
  • High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.
    Lancet Infect Dis. 2017
  • Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet.
    Mahana D, Kurtz ZD , Bokulich NA, Trent CM, Battaglia T, Chung J, Müller CL, Li H, Bonneau R, and Blaser MJ
    Genome Medicine 2016
  • Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.
    Heidkamp GF*, Sander J*, Lehmann CH, Heger L, Eissing N, Baranska A, Lühr JJ, Hoffmann A, Reimer K, Lux A, Söder S, Hartmann A, Zenk J, Ulas T, McGovern N, Alexiou C, Spriewald B, Mackensen A, Schuler, G, Schauf B, Forster A, Repp R, Fasching PA, Purbojo A, Cesnjevar R, Ullrich E, Ginhoux F, Schlitzer A, Nimmerjahn F, Schultze JL*, Dudziak D*
    Sci Immunol 2016
  • Multicenter quality assessment of 16S ribosomal DNA-sequencing for microbiome analyses reveals high inter-center variability.
    Hiergeist A, Reischl U, Gessner A.
    International Journal of Medical Microbiology. 2016
  • Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem.
    Hu Y, Zhang M, Lu B, Dai J
    Helicobacter 2016
  • Sparse and compositionally robust inference of microbial ecological networks.
    Kurtz ZD*, Müller CL*, Miraldi ER*, Littman DR, Blaser MJ, Bonneau RA
    PLoS Computational Biology 2015
  • Ferritin-mediated iron sequestration stabilizes Hypoxia-Inducible Factor-1α upon LPS activation in the presence of ample oxygen.
    Siegert, I., Schödel, J., Nairz, M., Schatz, V., Dettmer, K., Dick, C., Kalucka, J., Franke, K., Ehrenschwender, M., Schley, G., Beneke, A., Sutter, J., Moll, M., Hellerbrand, C., Wielockx, B., Katschinski, D.M., Lang, R., Galy, B., Hentze, M.W., Koivunen, P., Oefner, P.J., Bogdan, C., Weiss, G., Willam, C., Jantsch, J.
    Cell Rep. 2015
  • Low-oxygen tensions found in Salmonella-infected gut tissue boost Salmonella replication in macrophages by impairing antimicrobial activity and augmenting Salmonella virulence.
    Jennewein, J., Matuszak, J., Walter, S., Felmy, B., Gendera, K., Schatz, V., Nowottny, M., Liebsch, G., Hensel, M., Hardt, W.D., Gerlach, R.G.*, Jantsch, J.*
    Cell Microbiol. 2015
  • DNA transfer in the gastric pathogen Helicobacter pylori.
    Fernandez-Gonzalez E, Backert S
    J Gastroenterol 2014
  • Fe-S Cluster Biosynthesis Controls Uptake of Aminoglycosides in a ROS-Less Death Pathway.
    Ezraty B, Vergnes A, Banzhaf M, Duverger Y, Huguenot A, Brochado AR, Su SY, Espinosa L, Loiseau L, Py B, Typas A, Barras F
    Science 2013
  • High-resolution transcriptome maps reveal strain-specific regulatory features of multiple Campylobacter jejuni isolates.
    Dugar G, Herbig A, Förstner KU, Heidrich N, Reinhardt R, Nieselt K, Sharma CM
    PLoS Genetics 2013
  • High-throughput approaches to understanding gene function and mapping network architecture in bacteria.
    Brochado AR and Typas A
    Current Opinion in Microbiology 2013
  • Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies.
    Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova m, wex T, Tammer I, Schlueter D, Malfertheiner P
    Eur J Gastroenterol Hepatol 2013
  • Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.
    Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group participants
    GUT 2013
  • Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.
    Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA).
    Lancet Respir Med. 2013
  • Impact of Stoichiometry Representation on Simulation of Genotype-Phenotype Relationships in Metabolic Networks.
    Brochado AR, Andrejev S, Maranas CD and Patil KR
    PLoS Computational Biology 2012
  • European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report.
    Malfertheiner P et al.
    GUT 2012
  • Helicobacter pylori treatment in the era of increasing antibiotic resistance.
    Graham DY, Fischbach L
    GUT 2010
  • 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.
    Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG
    Antimicrob Agents Chemother. 2002
  • Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.
    Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE
    Antimicrob Agents Chemother. 1995